AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

are among 15 new drugs selected for the federal government’s new price negotiation program. Vraylar, which North Chicago-based AbbVie commercialized in 2015, is approved to treat major ...

Jan 10 (Reuters) - Abbvie (ABBV.N), opens new tab said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed ...

(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and ...

AbbVie on Friday said it will post a $3.5 billion impairment charge related to last year’s $8.7 billion bet on Cerevel Therapeutics following the failure of the deal’s key drug candidate.

With no other major drugs losing patent protection until the mid-2030s, capacity for more deals and upside from the new drugs, “we see AbbVie as well positioned,” JPMorgan analyst Christopher ...

By Christy Santhosh and Puyaan Singh (Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline ...